1 minute read
Jan. 17, 2022

Respiratory Case Study: An Inhaled JAK Inhibitor from GSK

“compound 54c”

inhaled JAK inhibitor reduced AO metabolism in lung from kinase-focused screening and SBDD Journal of Medicinal Chemistry GlaxoSmithKline, Stevenage, UK

twitterlinkedinprintemail